| Patents for C07K 5 - Peptides having up to four amino acids in a fully defined sequence; Derivatives thereof (30,692) |
|---|
| 07/30/2002 | US6426402 Respiratory system disorders; rheumatic diseases |
| 07/30/2002 | US6426331 Inhibitors of STAT function |
| 07/30/2002 | US6426073 Genetic engineered polypeptides |
| 07/30/2002 | US6426059 Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes |
| 07/30/2002 | CA2344707C N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives |
| 07/30/2002 | CA2068279C Method of crystallizing aspartame |
| 07/25/2002 | WO2002057413A2 Peptides for activation and inhibition of delta pkc |
| 07/25/2002 | WO2002057298A2 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/25/2002 | WO2002057225A2 Thrombin inhibitors |
| 07/25/2002 | WO2002038107A3 Stat modulators |
| 07/25/2002 | WO2002032874A3 Substituted heterocyclic compounds for treating multidrug resistance |
| 07/25/2002 | WO2002006306A3 SUBSTRATES AND ASSAYS FOR β-SECRETASE ACTIVITY |
| 07/25/2002 | WO2001055176A3 Methods for inhibiting smooth muscle cell proliferation |
| 07/25/2002 | WO2001003723A9 Hybrid polypeptides with enhanced pharmacokinetic properties |
| 07/25/2002 | WO2001000665A9 Inhibitors of memapsin 2 and use thereof |
| 07/25/2002 | US20020099042 Treating IL-1 mediated disease, autoimmune disease, inflammatory disease and neurodegenerative disease with ICE inhibitors characterized by specific structural and physicochemical features. |
| 07/25/2002 | US20020099041 Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
| 07/25/2002 | US20020098999 Compounds for sustained release of orally delivered drugs |
| 07/25/2002 | CA2433879A1 C-terminal modified oxamyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases |
| 07/24/2002 | EP1224212A1 Tetrapeptide stimulating functional activity of neurones, pharmacological agent based thereon and method of use thereof |
| 07/24/2002 | EP1224211A1 Process for the preparation of a dipeptide and intermediate product in such a process |
| 07/24/2002 | EP1224210A2 Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them |
| 07/24/2002 | EP1223984A2 Compounds that associate on the intermolecular level and aggregate bodies that contain them |
| 07/24/2002 | EP1223959A2 Inhbition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain |
| 07/24/2002 | EP1223945A1 Compositions comprising oxophosphonate-based metalloproteinase inhibitors |
| 07/24/2002 | EP1084132B1 Redox reversible imidazole-osmium complex conjugates |
| 07/24/2002 | EP0977726B1 Process for esterification of amino acids and peptides |
| 07/24/2002 | EP0886647B1 Serine protease inhibitors |
| 07/24/2002 | EP0836485B1 Cascade polymer complexes |
| 07/24/2002 | EP0835263B9 Somatostatin peptides |
| 07/24/2002 | EP0693941B1 Radiolabeled compounds for thrombus imaging |
| 07/24/2002 | CN1360563A Process for preparation of 3,3-dimethylbutanal |
| 07/24/2002 | CN1087955C Technetium-99m labeled imaging agents |
| 07/23/2002 | US6423869 Polyol-amino acid compounds having anti-helicobacter pylori activity |
| 07/23/2002 | US6423864 Desolventizing, diluting with water, cooling |
| 07/23/2002 | US6423840 Forming n-acylamino compound |
| 07/23/2002 | US6423723 Oral bioavailability |
| 07/23/2002 | US6423712 2,4-Substituted imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 07/23/2002 | US6423689 Peptidyl calcium channel blockers |
| 07/23/2002 | US6423688 Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 07/23/2002 | US6423684 WD-40 derived peptides and uses thereof |
| 07/23/2002 | US6423519 Contacting fungal cell with compound which inhibits prenyltransferase activity of cell, including permease tag which facilitates permease-mediated transport of compound into cell, inhibiting growth thereof |
| 07/23/2002 | US6423333 Sealing or filling tissue defects using polyfunctional crosslinking agents and protein polymers |
| 07/23/2002 | CA2069255C Granules of .alpha.-l-aspartyl-l-phenylalanine methyl ester |
| 07/18/2002 | WO2002055543A2 Hybrid peptides for treatment of bacteremia and septicemia |
| 07/18/2002 | WO2002055541A2 Peptides having inhibiting activity on the production of nitric oxide |
| 07/18/2002 | WO2002055540A1 New retinol derivatives, the method of preparations and the uses thereof |
| 07/18/2002 | WO2002055485A1 Prodrugs of excitatory amino acids |
| 07/18/2002 | WO2002055185A2 Block copolymers for multifunctional self-assembled systems |
| 07/18/2002 | WO2002055010A2 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 07/18/2002 | WO2002034202A3 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 07/18/2002 | WO2002008198A3 Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus |
| 07/18/2002 | WO2002002556A3 AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS α4 INTEGRIN ANTAGONISTS |
| 07/18/2002 | WO2001068142A9 Therapeutic and diagnostic ligand systems comprising transport molecule binding properties and medicaments containing the same |
| 07/18/2002 | US20020094957 Inhibits the polymerization of amyloid beta peptide; treating or preventing amyloidosis |
| 07/18/2002 | US20020094950 Preselected enzyme cleavage points are stable in blood but are cleavable within cells; use in drug delivery such as of antitumor agents |
| 07/18/2002 | CA2444637A1 Hybrid peptides for treatment of bacteremia and septicemia |
| 07/18/2002 | CA2434567A1 Pharmaceutical compositions comprising modified cns-derived peptides for promoting nerve regeneration and prevention of nerve degeneration |
| 07/17/2002 | EP1223175A1 Solid sweetener compositions, liquid sweetener compositions and utilization thereof |
| 07/17/2002 | EP1222199A1 N-formyl peptide receptor complex with a g-protein kinase signal pathway modification agent |
| 07/17/2002 | EP1221962A2 Inhibitors of proteasomal activity for stimulating bone and hair growth |
| 07/17/2002 | EP1221954A2 Methods for identifying inhibitors of methionine aminopeptidases |
| 07/17/2002 | EP1100520A4 Novel fluorescence dyes and their applications for whole cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof |
| 07/17/2002 | CN1359469A Epitopes formed by non-covalent association of conjugates |
| 07/17/2002 | CN1359390A Factor VII a inhibitors |
| 07/17/2002 | CN1359389A Substantially crystalline form of melagatran |
| 07/17/2002 | CN1359300A Uro-genital condition treatment system |
| 07/17/2002 | CN1358723A Novel bicyclic amino-pyrazino ketone compound, its preparation method and medicinal composition having same |
| 07/16/2002 | US6420591 Carbamates and compositions thereof, and methods for their use for treating cancer, inflammation, or a viral infection |
| 07/16/2002 | US6420561 Piperazinyl or piperidinyl acid derivatives for treatment of rheumatic diseases, arthritis due to gout and antiinflammatory agents |
| 07/16/2002 | US6420522 Enzyme inhibitors |
| 07/16/2002 | US6420438 1-amino-7-isoquinoline derivatives as serine protease inhibitors |
| 07/16/2002 | US6420401 1,2,5, thiadiazolidin-3-one 1,1-dioxide derivatives |
| 07/16/2002 | US6420380 Hepatitis C inhibitor tri-peptides |
| 07/16/2002 | CA2081869C Method for crystallization of .alpha.-l-aspartyl-l-phenylalanine methyl ester |
| 07/16/2002 | CA2069259C Method of crystallizing .alpha.-l-aspartyl-l-phenylalanine methyl ester |
| 07/11/2002 | WO2002053594A2 Inhibitors of memapsin 2 and use thereof |
| 07/11/2002 | WO2002053172A2 Use of matrix metalloproteinase peptide substrate to lower the rate of extracellular matrix turnover |
| 07/11/2002 | WO2002040507A3 Novel compounds for uses in radioimmunoscintigraphy and/or radioimmunotherapy of cancers |
| 07/11/2002 | WO2002027315A3 Compounds with a branched linker |
| 07/11/2002 | WO2002020724A3 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 07/11/2002 | WO2001085930A3 Methods and compounds for modulating melanocortin receptor ligand binding and activity |
| 07/11/2002 | WO2001068145A3 Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
| 07/11/2002 | WO2001018032A3 Dolastatin peptides |
| 07/11/2002 | WO2001017563A3 Integrin-mediated drug targeting |
| 07/11/2002 | WO2000075173A3 Peptide fragments of colostrinin |
| 07/11/2002 | US20020091125 Somatostatin antagonists and agonists that act at the SST subtype 2 receptor |
| 07/11/2002 | US20020091115 Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
| 07/11/2002 | US20020091089 (Substituted)acyl dipeptidyl inhibitors of the ICE/ced-3 family of cysteine proteases |
| 07/11/2002 | US20020091086 Peptides that block viral infectivity and methods of use thereof |
| 07/11/2002 | US20020090632 Measuring the concentration of preferential analyte in sample; obtain samples, incubate with binding particles, determine concentration of detectable particles |
| 07/11/2002 | CA2433446A1 Inhibitors of memapsin 2 and use thereof |
| 07/10/2002 | EP1221448A1 Sweetener compositions with high degree of sweetness having improved sweetness, corrigents and utilization thereof |
| 07/10/2002 | EP1220902A2 Conjugates between a peptide and a nucleic acid analog, such as a pna, lna or a morpholino |
| 07/10/2002 | EP1220871A2 Substituted phosphinate based peptide derivatives |
| 07/10/2002 | EP1220870A1 Metal-binding compounds and uses therefor |
| 07/10/2002 | EP1220869A1 Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death |
| 07/10/2002 | EP1220868A1 Extracorporeal endotoxin removal method |
| 07/10/2002 | EP1220852A1 Substituted diazepans |
| 07/10/2002 | CN1358197A Compositions and methods for cancer treatment by selectively inhibiting VEGF |